BioXyTran(BIXT)
NEEDHAM, MABiotechnology
Focus: BioXyTran is a public biotechnology company developing modified hemoglobin therapies, primarily focused on infectious disease indications including COVID-19. Founded in 2019 and headquartered in Needham, MA, the company operates at an early clinical stage with limited commercial infrastructure.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$150M
Open Jobs
0
About BioXyTran
AI assessmentNot HiringNo open roles listed right now. Follow BioXyTran to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Prolectin-M; a
COVID-19Clinical Trials (1)
NCT04512027Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.
N/AHelp build intelligence for BioXyTran
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.